Shukra Pharma.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE551C01044
  • NSEID:
  • BSEID: 524632
INR
39.61
1.83 (4.84%)
BSENSE

Feb 03

BSE+NSE Vol: 2.53 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy
Comparison
Company
Score
Quality
Valuation
Financial
Technical
Bliss GVS Pharma
Shukra Pharma.
Amrutanjan Healt
Syncom Formul.
Windlas Biotech
Hester Bios
Jagsonpal Pharma
Novartis India
Indoco Remedies
Solara Active
Beta Drugs Ltd
Why is Shukra Pharmaceuticals Ltd ?
1
Strong ability to service debt as the company has a low Debt to EBITDA ratio of 0.05 times
2
Healthy long term growth as Operating profit has grown by an annual rate 58.49%
3
Flat results in Sep 25
  • NET SALES(Q) At Rs 5.88 cr has Fallen at -32.4% (vs previous 4Q average)
  • PBT LESS OI(Q) At Rs -1.51 cr has Fallen at -165.0% (vs previous 4Q average)
  • PBDIT(Q) Lowest at Rs -0.42 cr.
4
With ROE of 18.2, it has a Very Expensive valuation with a 25.5 Price to Book Value
  • The stock is trading at a premium compared to its peers' average historical valuations
  • Over the past year, while the stock has generated a return of 526.60%, its profits have fallen by -17.2%
5
Despite the size of the company, domestic mutual funds hold only 0% of the company
  • Domestic mutual funds have capability to do in-depth on-the-ground research on companies- their small stake may signify either they are not comfortable at the price or the business
6
Consistent Returns over the last 3 years
  • Along with generating 526.60% returns in the last 1 year, the stock has outperformed BSE500 in each of the last 3 annual periods
stock-recommendationReal-Time Research Report
Verdict Report
How much should you hold?
  1. Overall Portfolio exposure to Shukra Pharma. should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Shukra Pharma. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Shukra Pharma.
66.39%
11.80
44.62%
Sensex
8.49%
0.43
11.83%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
26.81%
EBIT Growth (5y)
58.49%
EBIT to Interest (avg)
5.71
Debt to EBITDA (avg)
0.66
Net Debt to Equity (avg)
-0.15
Sales to Capital Employed (avg)
0.85
Tax Ratio
9.60%
Dividend Payout Ratio
4.57%
Pledged Shares
0
Institutional Holding
0.11%
ROCE (avg)
11.39%
ROE (avg)
14.72%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
145
Industry P/E
32
Price to Book Value
26.36
EV to EBIT
193.37
EV to EBITDA
141.85
EV to Capital Employed
30.69
EV to Sales
49.11
PEG Ratio
NA
Dividend Yield
0.03%
ROCE (Latest)
15.87%
ROE (Latest)
18.17%
Loading Valuation Snapshot...
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

14What is working for the Company
PAT(Latest six months)

At Rs 3.41 cr has Grown at 231.07%

OPERATING CF(Y)

Highest at Rs 7.92 Cr

NET SALES(Latest six months)

At Rs 11.27 cr has Grown at 28.95%

-11What is not working for the Company
NET SALES(Q)

At Rs 5.88 cr has Fallen at -32.4% (vs previous 4Q average

PBT LESS OI(Q)

At Rs -1.51 cr has Fallen at -165.0% (vs previous 4Q average

PBDIT(Q)

Lowest at Rs -0.42 cr.

OPERATING PROFIT TO NET SALES (Q)

Lowest at -7.14%

PAT(Q)

At Rs 2.38 cr has Fallen at -5.9% (vs previous 4Q average

NON-OPERATING INCOME(Q)

is 855.00 % of Profit Before Tax (PBT

Loading Valuation Snapshot...
Here's what is working for Shukra Pharma.
Operating Cash Flow - Annually
Highest at Rs 7.92 Cr
in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (Rs Cr)

Here's what is not working for Shukra Pharma.
Net Sales - Quarterly
At Rs 5.88 cr has Fallen at -32.4% (vs previous 4Q average)
over average Net Sales of the previous four quarters of Rs 8.70 Cr
MOJO Watch
Near term sales trend is very negative

Net Sales (Rs Cr)

Profit Before Tax less Other Income (PBT) - Quarterly
At Rs -1.51 cr has Fallen at -165.0% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 2.32 Cr
MOJO Watch
Near term PBT trend is very negative

PBT less Other Income (Rs Cr)

Operating Profit (PBDIT) - Quarterly
Lowest at Rs -0.42 cr.
in the last five quarters
MOJO Watch
Near term Operating Profit trend is negative

Operating Profit (Rs Cr)

Operating Profit Margin - Quarterly
Lowest at -7.14%
in the last five quarters
MOJO Watch
Company's efficiency has deteriorated

Operating Profit to Sales

Profit Before Tax less Other Income (PBT) - Quarterly
Lowest at Rs -1.51 cr.
in the last five quarters
MOJO Watch
Near term PBT trend is negative

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
At Rs 2.38 cr has Fallen at -5.9% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 2.53 Cr
MOJO Watch
Near term PAT trend is negative

PAT (Rs Cr)

Non Operating Income - Quarterly
is 855.00 % of Profit Before Tax (PBT)
MOJO Watch
The company's income from non business activities is high; which is not a sustainable business model

Non Operating Income to PBT

Non Operating Income - Quarterly
Highest at Rs 1.71 cr
in the last five quarters
MOJO Watch
Increased income from non business activities may not be sustainable

Non Operating Income